Janssen's JNJ-79635322 Leads Global Race in BCMA/GPRC5D/CD3 Trispecific Antibody for RRMM; Four Domestic Candidates Advance in Clinical Development
Johnson & Johnson
Medical Device R&D and Manufacturer
Note:This article does not constitute any investment opinions or suggestions; please refer to official/company announcements for accuracy.This article only introduces drugs related to medical health, not a recommendation of treatment options (if involved), and does not represent the platform's position.Any article reprinted needs to be authorized.
2025Year12Month2Day, Johnson & Johnson in ClinicalTrials.gov Registered the world's firstBCMA/GPRC5D/CD3Three Antibiotics JNJ-79635322TheIIIPhase Clinical Trial Trilogy-4, used for the treatment of relapsed or refractory multiple myeloma (RRMM). This study aims to compare JNJ-79635322Vs.BCMA×CD3Bispecific antibodies in patients who have received at least3Previous treatments (including proteasome inhibitors, immunomodulators, and anti-CD38Antibody)RRMM Efficacy in patients.
The study plans to include400N patients, the trial was divided into two groups, with the experimental group receiving subcutaneous injections.JNJ-79635322Until disease progression or intolerance, the control group was subcutaneously injected.Teclistamab，The primary endpoint was the objective response rate (ORR) and progression-free survival (PFS）。
PreviouslyAt Johnson & Johnson2025American Society of Clinical Oncology (ASCO)ASCO) Annual MeetingAnnouncedFinishedJNJ-79635322Preliminary Phase I Clinical Results（NCT05652335），126Number of Patients Treated，100mgSubcutaneous injection, every4Week1Times,Before the first dose5mgIncremental Dose to ReduceCRS Risk. The treatment drug in patients who have not receivedBCMA/GPRC5D Targeted TherapyRRMMAmong patientsORRReach100%, deep and sustained relief, fast initial relief (1.2months). In terms of safety, the most common adverse event was cytokine release syndrome (CRS), Incidence rate is59%, but did not appear3Level and above incidents.28%The patients experienced3Infections of grade and above.5Example: Patients experienced dose-limiting toxicity, and another4Example of a death report during treatment due to adverse events, where1Death case was triggered by drug-related adenovirus encephalitis. The incidence rate of taste-related adverse events is58%, most are1Level. Others withGPRC5DThe incidence of related adverse oral events was low: the incidence of dry mouth was17%(InRP2DDose group did not appear2Grade Event), the incidence of dysphagia is less than4%（RP2DNo relevant reports in the dose group). In addition,1/2Grade Weight Loss inRP2DThe incidence rate in the dose group is6%, Full-dose Group:12%, Not observed3Weight loss events of grade and above.
Multiple myeloma is a hematologic malignancy that affects plasma cells, a type of white blood cell found in the bone marrow.In multiple myeloma, these malignant plasma cells proliferate abnormally, gradually replacing normal cells in the bone marrow. JNJ-79635322Adopting a new and unique molecular structure, its design draws inspiration from two approved first-in-class bispecific antibodies.- TeclistamabAndTalquetamabR&D experience. Different from these two bispecific antibodies, JNJ-79635322Is a single-molecule drug that can simultaneously bind to three different targets: respectively targeting the surface of multiple myeloma cells.BCMA（BCell Maturation Antigen) andGPRC5D（GProtein-coupled receptor C5D), and T Cell SurfaceCD3Molecule. By dual-targeting myeloma cell antigens, it aims to overcome tumor heterogeneity while inhibiting the development of drug resistance.
Currently, there is no targetedBCMA/GPRC5D/CD3The listing of the three-antibody drug, in addition toJNJ-79635322There are also four products in the clinical stage,All are domestically produced drugs, mainly used for the treatment of relapsed or refractory multiple myeloma.
BCMA/GPRC5D/CD3Tri-specific antibody demonstrates significant clinical value in treating relapsed or refractory multiple myeloma due to its unique mechanism of action.JNJ-79635322TheIIIThe trial period isRRMMTreatment Injects New Momentum, China-Produced Tri-Specific Antibodies Compete in Sync: Breakthroughs in the Tri-Specific Antibody Field Are Worth Anticipating.
Source of Information:1、https://clinicaltrials.gov
2、https://www.prnewswire.com
2025Year12Month2Day, Johnson & Johnson in ClinicalTrials.gov Registered the world's firstBCMA/GPRC5D/CD3Three Antibiotics JNJ-79635322TheIIIPhase Clinical Trial Trilogy-4, used for the treatment of relapsed or refractory multiple myeloma (RRMM). This study aims to compare JNJ-79635322Vs.BCMA×CD3Bispecific antibodies in patients who have received at least3Previous treatments (including proteasome inhibitors, immunomodulators, and anti-CD38Antibody)RRMM Efficacy in patients.
The study plans to include400N patients, the trial was divided into two groups, with the experimental group receiving subcutaneous injections.JNJ-79635322Until disease progression or intolerance, the control group was subcutaneously injected.Teclistamab，The primary endpoint was the objective response rate (ORR) and progression-free survival (PFS）。
PreviouslyAt Johnson & Johnson2025American Society of Clinical Oncology (ASCO)ASCO) Annual MeetingAnnouncedFinishedJNJ-79635322Preliminary Phase I Clinical Results（NCT05652335），126Number of Patients Treated，100mgSubcutaneous injection, every4Week1Times,Before the first dose5mgIncremental Dose to ReduceCRS Risk. The treatment drug in patients who have not receivedBCMA/GPRC5D Targeted TherapyRRMMAmong patientsORRReach100%, deep and sustained relief, fast initial relief (1.2months). In terms of safety, the most common adverse event was cytokine release syndrome (CRS), Incidence rate is59%, but did not appear3Level and above incidents.28%The patients experienced3Infections of grade and above.5Example: Patients experienced dose-limiting toxicity, and another4Example of a death report during treatment due to adverse events, where1Death case was triggered by drug-related adenovirus encephalitis. The incidence rate of taste-related adverse events is58%, most are1Level. Others withGPRC5DThe incidence of related adverse oral events was low: the incidence of dry mouth was17%(InRP2DDose group did not appear2Grade Event), the incidence of dysphagia is less than4%（RP2DNo relevant reports in the dose group). In addition,1/2Grade Weight Loss inRP2DThe incidence rate in the dose group is6%, Full-dose Group:12%, Not observed3Weight loss events of grade and above.
Multiple myeloma is a hematologic malignancy that affects plasma cells, a type of white blood cell found in the bone marrow.In multiple myeloma, these malignant plasma cells proliferate abnormally, gradually replacing normal cells in the bone marrow. JNJ-79635322Adopting a new and unique molecular structure, its design draws inspiration from two approved first-in-class bispecific antibodies.- TeclistamabAndTalquetamabR&D experience. Different from these two bispecific antibodies, JNJ-79635322Is a single-molecule drug that can simultaneously bind to three different targets: respectively targeting the surface of multiple myeloma cells.BCMA（BCell Maturation Antigen) andGPRC5D（GProtein-coupled receptor C5D), and T Cell SurfaceCD3Molecule. By dual-targeting myeloma cell antigens, it aims to overcome tumor heterogeneity while inhibiting the development of drug resistance.
Currently, there is no targetedBCMA/GPRC5D/CD3The listing of the three-antibody drug, in addition toJNJ-79635322There are also four products in the clinical stage,All are domestically produced drugs, mainly used for the treatment of relapsed or refractory multiple myeloma.
BCMA/GPRC5D/CD3Tri-specific antibody demonstrates significant clinical value in treating relapsed or refractory multiple myeloma due to its unique mechanism of action.JNJ-79635322TheIIIThe trial period isRRMMTreatment Injects New Momentum, China-Produced Tri-Specific Antibodies Compete in Sync: Breakthroughs in the Tri-Specific Antibody Field Are Worth Anticipating.
Source of Information:1、https://clinicaltrials.gov
2、https://www.prnewswire.com
Copyright statement: This article is reproduced from Pharmaron, Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
Copyright statement: This article is reproduced from Pharmaron, Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
Copyright statement: This article is reproduced from Pharmaron, Media or individuals who do not wish to be reprinted can contact us, and we will delete it immediately.
